胰腺癌空间构型与新辅助治疗和根治性切除术后疾病复发相关
Spatial Configuration of Pancreatic Cancer Is Associated with Disease Recurrence after Neoadjuvant Therapy and Curative-Intent Resection.
从标准H&E切片量化的残留癌-间质拓扑结构在PDAC新辅助治疗后产生独立预后信号,为空间风险提供细胞免疫相关性依据,并推动前瞻性验证及空间信息指导的辅助治疗策略。
英文原题:Machine learning for MRI radiomics: a study predicting tumor-infiltrating lymphocytes in patients with pancreatic ductal adenocarcinoma.
由XGBoost构建的模型能够预测PDAC TILs,并可能有助于免疫治疗的临床决策。
开发并验证一种基于磁共振成像(MRI)的机器学习分类器,用于术前预测胰腺导管腺癌(PDAC)患者的TIL(肿瘤浸润淋巴细胞)(TILs)。
在这项回顾性研究中,156例PDAC患者接受了MR扫描和手术切除。使用免疫组织化学检测并定量CD4、CD8和CD20的表达,并通过Cox回归模型获得TILs评分。将所有患者分为TILs评分低组和TILs评分高组。使用最小绝对收缩和选择算子法以及极端梯度提升(XGBoost)来选择特征并构建预测模型。使用训练队列(116例患者)和验证队列(40例患者)评估模型的性能,并应用决策曲线分析(DCA)用于临床使用。
XGBoost预测模型在训练集(AUC 0.86;95% CI 0.79-0.93)和验证集(AUC 0.79;95% CI 0.64-0.93)中均显示出良好的区分度。训练集的灵敏度、特异度和准确度分别为86.67%、75.00%和0.81,而验证集分别为84.21%、66.67%和0.75。决策曲线分析表明XGBoost分类器具有临床实用性。
OBJECTIVE: To develop and validate a machine learning classifier based on magnetic resonance imaging (MRI), for the preoperative prediction of tumor-infiltrating lymphocytes (TILs) in patients with pancreatic ductal adenocarcinoma (PDAC). MATERIALS AND METHODS: In this retrospective study, 156 patients with PDAC underwent MR scan and surgical resection. The expression of CD4, CD8 and CD20 was detected and quantified using immunohistochemistry, and TILs score was achieved by Cox regression model. All patients were divided into TILs score-low and TILs score-high groups. The least absolute shrinkage and selection operator method and the extreme gradient boosting (XGBoost) were used to select the features and to construct a prediction model. The performance of the models was assessed using the training cohort (116 patients) and the validation cohort (40 patients), and decision curve analysis (DCA) was applied for clinical use. RESULTS: The XGBoost prediction model showed good discrimination in the training (AUC 0.86; 95% CI 0.79-0.93) and validation sets (AUC 0.79; 95% CI 0.64-0.93). The sensitivity, specificity, and accuracy for the training set were 86.67%, 75.00%, and 0.81, respectively, whereas those for the validation set were 84.21%, 66.67%, and 0.75, respectively. Decision curve analysis indicated the clinical usefulness of the XGBoost classifier. CONCLUSION: The model constructed by XGBoost could predict PDAC TILs and may aid clinical decision making for immune therapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。